Genetic Study of Children With Soft Tissue Sarcoma or Rha... | NCT00003793

NCT00003793

ID	Type	Description
COG-AB9804	Other Identifier	Children's Oncology Group
CCG-B9804	Other Identifier	Children's Cancer Group
CDR0000066936	Other Identifier	Clinical Trials.gov

Status Module

Sponsor/Collaborators Module

Name	Class
National Cancer Institute (NCI)	NIH

Oversight Module

Description Module

Conditions Module

Design Module

Interventional Study Design

Biospecimen

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Identification of Genetical suceptibility prior to therapy		Determine the glutathione-s-transferase theta (GSTT1) or glutathione-s-transferase mu (GSTM1) null genotype is more frequent in individuals with t-MDS/AML. Determine the GSTT1 or GSTM1 null genotype is associated with a reduced incidence of relapse of sarcoma. Determine NAT2 or CYP1A1 genotype influences risk of t-MDS/AML. Determine development of a "mutator phenotype" as demonstrated by developing microsatellite instability is an early marker of individuals likely to progress to t-MDS/AML.	Genetic: microsatellite instability analysis Genetic: mutation analysis
Increased Risk Of T-MDS/AML before/after Therapy		Determine clonal hematopoiesis develops in children receiving high intensity alkylating agent chemotherapy for sarcomas. Determine development of clonal hematopoiesis is associated with increased frequency of t-MDS/AML. Determine measurement of somatic cell mutation frequency, measured by the glycophorin A (GPA) assay prior to and after chemotherapy will predict individuals at increased risk of t-MDS/AML. Identify individuals with ras gene mutations in normal peripheral blood cells after therapy, and whether the identification of such mutations is associated with increased risk of t-MDS/AML blood cells after therapy, and whether the identification of such mutations is associated with increased risk of t-MDS/AML.	Genetic: clonality analysis Genetic: microsatellite instability analysis Genetic: mutation analysis

Name	Type	Description	Arm Group Labels	Other Names
clonality analysis	Genetic		Increased Risk Of T-MDS/AML before/after Therapy
microsatellite instability analysis

Outcomes Module

Measure	Description	Time Frame
Event Free Survival

Eligibility Module

Contacts/Locations Module

Name	Affiliation	Role
Stella M. Davies, MBBS, PhD	Children's Hospital Medical Center, Cincinnati	Study Chair

Facility	Status	City	State	ZIP	Country	Contacts
Southern California Permanente Medical Group		Downey	California	90242	United States
Jonathan Jaques Children's Cancer Center at Miller Children's Hospital

References Module

No data available